US2020018682A1PendingUtilityA1

Early post-transfection isolation of cells (epic) for biologics production

Assignee: GENZYME CORPPriority: Oct 9, 2015Filed: Apr 23, 2019Published: Jan 16, 2020
Est. expiryOct 9, 2035(~9.2 yrs left)· nominal 20-yr term from priority
G01N 15/14C12N 15/1086G01N 33/5044G01N 2333/70592C07K 2317/10C12N 15/85C07K 16/00C12N 2510/02G01N 2015/149G01N 15/149G01N 33/537
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are methods for selecting a population of cells expressing a target polypeptide. In some aspects, the disclosure provides methods for sorting and selecting populations of transfected host cells based on their early expression of a selectable polypeptide. In certain embodiments, the sorting is performed using fluorescence-activated cell sorting or magnetic-activated cell sorting based on the selectable polypeptide. Such selection methods can be further utilized to generate clonal populations of producer cells, e.g. for large-scale manufacturing of a target polypeptide of interest.

Claims

exact text as granted — not AI-modified
1 - 30 . (canceled) 
     
     
         31 . A method of producing a population of producer cells expressing a target polypeptide, the method comprising:
 (a) transfecting host cells with one or more vectors that encode one or more mRNAs, wherein the one or more mRNAs encode a selectable polypeptide and the target polypeptide;   (b) isolating from the transfected host cells, within 2 to 15 days of transfection, a sub-population of early-expressing transfected host cells which express the selectable polypeptide; and   (c) expanding the sub-population of transfected host cells, thereby producing a population of producer cells expressing the target polypeptide.   
     
     
         32 . The method of  claim 31 , wherein steps (b) and (c) are each performed in drug-selection-free medium. 
     
     
         33 . The method of  claim 31 , further comprising isolating the target polypeptide from the population of producer cells. 
     
     
         34 . The method of  claim 31 , further comprising isolating one or more single transfected host cells from the expanded sub-population and culturing the one or more single transfected host cells to produce clonal populations of the one or more single transfected host cells. 
     
     
         35 . The method of  claim 34 , wherein at least one of the clonal populations of the one or more single transfected host cells yields a 2- to 30-fold improvement in production of the target polypeptide compared to that of a stable pool of transfected but uncloned host cells obtained at step (c). 
     
     
         36 . The method of  claim 31 , wherein the transfected host cells subject to selection in (b) contains at least 80-120×10 6  cells. 
     
     
         37 . The method of  claim 31 , wherein the isolating in step (b) is performed less than 6 days after transfection. 
     
     
         38 . The method of  claim 31 , wherein the sub-population of transfected host cells contains 0.5-6.0×10 6  cells prior to expansion in step (c). 
     
     
         39 . The method of  claim 31 , wherein the expanding in step (c) is for between 4-31 days. 
     
     
         40 . The method of  claim 31 , wherein a first of the one or more vectors encodes the mRNA encoding the target polypeptide and a second of the one or more vectors encodes the mRNA encoding the selectable polypeptide. 
     
     
         41 . The method of  claim 31 , wherein the mRNA encoding the target polypeptide and the mRNA encoding the selectable polypeptide are both encoded on one vector. 
     
     
         42 . The method of  claim 31 , wherein the target polypeptide and the selectable polypeptide form a fusion polypeptide. 
     
     
         43 . The method of  claim 31 , wherein the target polypeptide and the selectable polypeptide are encoded by a single multicistronic mRNA. 
     
     
         44 . The method of  claim 43 , wherein the multicistronic mRNA comprises a first open reading frame (ORF) that encodes the selectable polypeptide and a second ORF that encodes the target polypeptide, wherein the first ORF is 5′ to the second ORF. 
     
     
         45 . The method of  claim 44 , wherein the first ORF has a non-AUG start codon. 
     
     
         46 . The method of  claim 44 , wherein the second ORF has an AUG start codon. 
     
     
         47 . The method of  claim 44 , wherein the ORF that encodes the selectable polypeptide is devoid of any AUG sequences. 
     
     
         48 . The method of  claim 31 , wherein the selectable polypeptide is CD52 or CD59. 
     
     
         49 . A clonal population of transfected host cells that express a selectable polypeptide and a target polypeptide obtainable by the method of  claim 31 . 
     
     
         50 . The clonal population of  claim 49 , wherein the clonal population yields a 2- to 30-fold improvement in production of the target polypeptide compared to that of the sub-population of transfected host cells in (b).

Join the waitlist — get patent alerts

Track US2020018682A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.